Table 2.

Treatment Information and Related Outcomes for New Allopurinol Users

Prescriber Specialty Initiated Allopurinol Rx (n,%)	N=13,341
Family medicine	6,796 (50.9)
Internal medicine	4,296 (32.2)
Rheumatology	805 (6.0)
Other	1,444 (10.8)
Starting Allopurinol Dose, mg/day (n,%)	N= 13,341
50 mg/day	126 (0.9)
100 mg/day	6,382 (47.8)
>100 mg to <300 mg/day	1,761 (13.2)
300 mg/day	4,981 (37.3)
>300 mg/day	91 (0.7)
Allopurinol Treatment	N= 13,341
Patients with only one dispensing, n (%)	2,350 (17.6)
Duration of treatment for single Rx, mean days, SD	93.3±21.0
Patients receiving more than single dispensing, n (%)	10,991 (82.4)
Duration of treatment, mean years, SD	2.6±1.6
Dose escalation during observation, n (%)	2,994 (22.4)
Dose decrease during observation, n (%)	817 (6.1)
No Dose Change during observation, n (%)	9,530 (71.4)
Allopurinol Adherence (PDC), %*a	N= 13,341
Proportion of Days Covered (PDC) mean, SD	65.2±23.2
Adherent (PDC ≥ 80%), n (%)	4,454 (33.4)
Nonadherent (PDC < 80%), n (%)	8,886 (66.6)
Allopurinol Adherence (PDC)* For Patients with ≥ 2 Dispensingsb	N= 10,991
PDC mean, SD	74.2±21.4
Adherent (PDC ≥ 80%), n (%)	4,656 (42.4)
Nonadherent (PDC < 80%), n (%)	6,335 (57.6)
Serum Urate (sUA)C	N= 9,581
sUA level at end of observation, mean, SD	6.9±1.8
Patients at sUA goal (<6mg/dl) at end of observation, n (%)	3,078 (32.1)
Patients’ Last sUA Level, n (mean sUA ± SD)d	N= 9,581
31-90 days	643, 6.5±1.7
91-180 days	674, 6.9±1.9
181-270 days	541, 6.9±1.7
271-365 days	563, 6.7±1.8
> 365 days	7,160, 6.9±1.8

^*Calculated during 12 months post-index.

^aPDC calculation included patients with one or more allopurinol dispensing.

^bPDC calculation focused on only patients with 2 or more allopurinol dispensings.

^CPatients with a baseline sUA level and had one level during follow-up and was the last level before follow-up.

^dCategorized by days from baseline.

Standard deviation (SD); proportion of days covered (PDC); serum urate (sUA).